Camurus
631
SEK
+5.34 %
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
8 following
www.camurus.com/sv/investerare
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Revenue
1.72B
EBIT %
30.63 %
P/E
81.11
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CAMX
Daily low / high price
584.5 / 631
SEK
Market cap
37.11B SEK
Turnover
114.04M SEK
Volume
186K
Latest videos
Financial calendar
Interim report
2024-11-07
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sandberg Development AB | 35.0 % | 35.2 % |
Fjärde AP-fonden | 4.5 % | 4.5 % |
JP Morgan Chase Bank | 3.6 % | 3.6 % |
Swedbank Robur Fonder | 3.3 % | 3.4 % |
Avanza Pension | 2.9 % | 3.0 % |
Fredrik Tiberg | 2.8 % | 2.8 % |
Handelsbanken Fonder | 2.6 % | 2.6 % |
State Street Bank and Trust | 2.6 % | 2.6 % |
The Bank of New York Mellon SA/NV | 1.5 % | 1.5 % |
Norges Bank | 1.2 % | 1.2 % |
ShowingAll content types
Camurus AB: Camurus' Interim Report Third Quarter 2024
Camurus AB: Camurus delårsrapport tredje kvartalet 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools